Carrier Screening Market Top Companies
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Natera Inc.
- Myriad Genetics Inc.
- Invitae Corporation
- Fulgent Genetics
- Eurofins Scientific
- Centogene N.V.
- OPKO Health (GeneDx)
- Laboratory Corporation of America Holdings (Labcorp)
- Quest Diagnostics Incorporated
- 23andMe, Inc.
- BGI Genomics Co., Ltd.
- Color Health, Inc.
- Sema4
- Ambry Genetics
- Baylor Genetics
- MedGenome Inc.
- Dante Labs
- PerkinElmer Inc
Market Growth
The global carrier screening market size is calculated at US$ 2.58 billion in 2024, grew to US$ 3.09 billion in 2025, and is projected to reach around US$ 15.5 billion by 2034. The market is expanding at a CAGR of 19.65% between 2025 and 2034.
What are the Major Drifts in the Carrier Screening Market?
- In 2025, the growing demand for tailored medicine, supportive government initiatives, and expanding healthcare infrastructure are fueling the comprehensive expansion of the market.
- In June 2025, Lexeo Therapeutics secured $40 million investment for cardiac genetic disease therapies using a novel non-viral RNA platform.
- In February 2025, Ubie, a global healthcare AI platform, and Nucleus Genomics, the next-generation genetic testing and analysis company, entered into a strategic partnership to expand access to genetic screening and early disease detection.
- In January 2025, Singapore-headquartered healthcare investor August Global Partners (AGP) invested in Vietnam-based genomic testing company Gene Solutions (GS) through a proprietary funding round.
Value Chain Analysis
R&D
The carrier screening market usually consists of the designing of novel genetic tests by first reviewing and refining evolved scientific knowledge, establishing new methods for sample collection and analysis, validating test precision and reliability, and ultimately developing accessible reporting systems with genetic counseling to interpret results for patients.
Key Players: Natera, Myriad Genetics, LabCorp, Invitae, and Fulgent Genetics
Clinical Trials and Regulatory Approvals
It involves confirmation of accuracy and safety, as well as other laboratory processes like analytical validation, regulatory submission to bodies such as the FDA, and consistent quality control, with post-market surveillance to monitor performance.
Key Players: American College of Medical Genetics and Genomics (ACMG), US FDA, Merck, Ferring Pharmaceuticals, etc.
Patient Support and Services
The carrier screening market gives genetic counseling to assess results and guide decision-making, pre-test education on inheritance patterns and possible risks, and post-test support for handling psychological aspects and informing family members.
Key Players: MedGenome, Medicover Genetics, BGI Genomics, Medicover Genetics, etc.
Latest Announcements by Industry Leaders
- In August 2025, Rady Children’s Institute for Genomic Medicine (RCIGM®) announced an innovative international partnership with Sidra Medicine, a leading specialty healthcare organization, to implement a major milestone as Sidra Medicine becomes the first international site of the BeginNGS genome-based newborn screening program. Dr. Akil replied that BeginNGS develops upon their successful NOOR-QATAR efforts by integrating state-of-the-art genomics tools.
- In May 2025, Frame, the collaborative care platform transforming access to reproductive and fertility care, announced a strategic alliance with Labcorp, a leading player in innovative and comprehensive laboratory services, to allow patients to seamlessly access Labcorp's comprehensive suite of fertility testing services, mainly hormone and genetic testing. Dr. Pouneh Alizadeh, OB/GYN and Medical Director at Frame, commented that this will offer patients the required accessibility and convenience of testing for an excellent understanding of their health and fertility.
What are the Key Developments in the Carrier Screening Market?
- In August 2025, Abu Dhabi launched newborn genetic screening to detect over 800 childhood conditions.
- In May 2025, BillionToOne, Inc., a molecular diagnostics company, launched an expanded offering for providers utilizing the UNITY Fetal Risk™ Screen.
- In July 2025, Gujarat unveiled India’s first tribal genome project to tackle inherited diseases.
- In March 2025, Bio-Techne Corporation’s Asuragen, a Bio-Techne brand, collaborated with Oxford Nanopore Technologies to introduce the AmplideX Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening research.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
